Departments of Environmental Medicine and Medicine, NYU Langone Medical Center, Tuxedo, NY 10987, USA; Departments of Medicine and Pathology and Immunology, the Michael E. DeBakey VA Medical Center, and the Biology of Inflammation Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Medicine, NYU Langone Medical Center, New York, NY 10016, USA; Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Medicine, Baltimore, MD 21218, USA.
Received January 23, 2012; accepted March 5, 2012; Epub April 23, 2012; Published June 30, 2012
Abstract: This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from discovery of the molecule, the identification of its pathogenic role in animal models of asthma, to the development of clinically successful neutralizing agents. The translational path from basic research to clinical application was not sequential as expected but random with respect to the tools (molecular; cell biology, animal models, human studies) used and to the application of academic versus industry research. The experiences with the development of neutralizing anti-IL-13 reagents emphasize the need for inclusion of a biomarker assay in the clinical trials that both identifies individuals that actually have aberrant expression of the pathway of interest and allows determining whether the target of interest is neutralized. (AJCEI1201001).
full text PDF
No comments:
Post a Comment